Halle/Saale, July 6, 2010 — Probiodrug AG (Probiodrug), a biotech company developing novel concepts and products for the treatment of neurodegenerative and inflammatory diseases with a […]
Halle/Saale, June 17, 2010 – Probiodrug AG (Probiodrug), a biotech company developing novel concepts and products for the treatment of neurodegenerative and inflammatory diseases with a […]
Halle/Saale, June 16, 2010 — Probiodrug AG (Probiodrug), a biotech company developing novel concepts and products for the treatment of neurodegenerative and inflammatory diseases with a […]
Halle/Saale, June 15, 2010 — Probiodrug AG (Probiodrug), a biopharmaceutical company developing novel concepts and products for the treatment of neurodegenerative and inflammatory diseases with a […]
Appointment of Claus Braestrup as Chairman of the Supervisory Board Halle/Saale, June 14, 2010 — Probiodrug AG (Probiodrug), a biotech company developing novel concepts and products […]
Company wins BB Biotech and Edmond de Rothschild Investment Partners as co – lead investors, joined by LSP Life Science Partners, Biogen Idec New Ventures and […]
Pyroglutamated Aß and Neuroinflammation: Targeting fundamentals of AD pathogenesis by QC inhibition. Halle / Saale, July 11, 2009 — Probiodrug AG (Probiodrug), a developer of small […]
Halle/Saale, May 15, 2009 — Probiodrug AG (Probiodrug), a developer of small molecule inhibitors for the treatment of inflammatory and neurodegenerative diseases, announced today that no […]
Pyroglutamated Aß and Neuroinflammation: Targeting fundamentals of AD pathogenesis by QC inhibition. Halle/Saale, March 11, 2009 — Probiodrug AG (Probiodrug), a developer of small molecule inhibitors […]